The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.
The management of Central Centrifugal Cicatricial Alopecia (CCCA) is challenging due to limited current treatments and a lack of randomized controlled trials. Management focuses on behavioral and styling modifications, in addition to symptomatic relief. Any potentially damaging hair care practices such as chemical relaxers, heat application to the scalp, and the use of hardening gels and sprays are discouraged. Many commonly used therapies are anti-inflammatory in nature, including intralesional steroids, topical steroids, oral antibiotics and increased frequency of hair washing with antidandruff shampoos. These treatments not only lead to improvement in pruritus and tenderness, but in some cases result in increased hair density. Currently, comparison studies of different treatments for CCCA subjects is limited. The aim is to determine if there is an advantage in using one particular anti-inflammatory therapy over another for relieving symptoms and promoting hair follicle regrowth.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
Wake Forest University Health Scieces
Winston-Salem, North Carolina, United States
Amount of hair loss regression
measured by standardized photos and dermatoscope photos
Time frame: Baseline
Amount of hair loss regression
measured by standardized photos and dermatoscope photos
Time frame: Month 2
Amount of hair loss regression
measured by standardized photos and dermatoscope photos
Time frame: Month 4
Amount of hair loss regression
measured by standardized photos and dermatoscope photos
Time frame: Month 6
Amount of hair regrowth
measured by standardized photos and dermatoscope photos
Time frame: Months 2, 4, and 6
Amount of alleviation of signs and symptoms of disease
Higher scores means worse symptoms and signs of disease - Clinical signs and symptoms of CCCA will be documented by administering a standardized questionnaire to all subjects. Subjects will complete the standardized questionnaire regarding symptoms of their hair loss at the start of the enrollment and every 2 months until the study is completed.
Time frame: Months 2, 4, and 6
Dermatology Life Quality Index (DLQI)
Scores of "not at all" to "very much"
Time frame: Baseline and Month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.